AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
AEON Biopharma, Inc. Class A (AEON)
Company Research
Source: GlobeNewswire
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, today announced its financial results for t
Show less
Read more
Impact Snapshot
Event Time:
AEON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEON alerts
High impacting AEON Biopharma, Inc. Class A news events
Weekly update
A roundup of the hottest topics
AEON
News
- AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting SchedulingGlobeNewswire
- AEON Biopharma (NASDAQ:AEON) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- AEON Biopharma (NASDAQ:AEON) had its "buy" rating reaffirmed by analysts at Aegis. They now have a $7.20 price target on the stock.MarketBeat
AEON
Sec Filings
- 12/4/25 - Form 8-K
- 11/14/25 - Form DEFA14A
- 11/14/25 - Form 10-Q
- AEON's page on the SEC website